Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours

Trial Profile

A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; HTL 0039732 (Primary)
  • Indications Bladder cancer; Cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Mesothelioma; Pancreatic cancer; Phaeochromocytoma; Prostate cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man

Most Recent Events

  • 08 Jun 2025 Planned End Date changed from 1 Sep 2026 to 1 Jun 2027.
  • 08 Jun 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Jun 2027.
  • 17 Sep 2024 Trial design were presented at the 49th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top